Markel Group Inc. Decreases Stake in IQVIA Holdings Inc. $IQV

Markel Group Inc. decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.5% in the third quarter, Holdings Channel reports. The fund owned 46,900 shares of the medical research company’s stock after selling 2,742 shares during the period. Markel Group Inc.’s holdings in IQVIA were worth $8,908,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in IQV. Asset Dedication LLC grew its holdings in IQVIA by 224.0% in the 2nd quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after buying an additional 168 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new stake in IQVIA during the second quarter worth about $39,000. J.Safra Asset Management Corp raised its stake in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the period. Rothschild Investment LLC grew its stake in shares of IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after buying an additional 124 shares during the period. Finally, Root Financial Partners LLC acquired a new stake in shares of IQVIA during the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 1.7%

NYSE IQV opened at $239.28 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The firm has a market cap of $40.75 billion, a price-to-earnings ratio of 32.82, a PEG ratio of 2.39 and a beta of 1.36. The firm has a 50 day simple moving average of $229.57 and a 200-day simple moving average of $206.73. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same period in the prior year, the business earned $2.84 EPS. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IQV has been the subject of several analyst reports. UBS Group increased their price objective on IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Truist Financial raised their price objective on IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Barclays set a $230.00 price objective on shares of IQVIA in a report on Monday, December 15th. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, BMO Capital Markets started coverage on shares of IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.